Proven science. New technology.

Our current therapeutic focus is the continued development of the novel drug, lotilaner.

 

By applying our unique approach to research and development, we’re investigating solutions to target meibomian gland disease (MGD), rosacea, Lyme disease prevention, and community reduction of malaria.

Our Pipeline

We’re looking for new ways to apply proven science to solve large problems. Our pipeline of wholly owned candidates addresses a number of diseases with high unmet needs across a range of therapeutic categories including eye care, dermatology, and infectious disease prevention.

Candidate
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Meibomian gland disease
(MGD)
XDEMVY®*
(TP-03)
Demodex blepharitis
(preservative free)
Preservative-free formulation to be tested after NDA submission
Demodex blepharitis
and MGD in China
(partnership with LianBio)
TP-04
Rosacea
Lyme disease
TP-05
Malaria
XDEMVY®*
TP-03
TP-04
TP-05
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
Meibomian gland disease (MGD)
Demodex blepharitis (preservative free)
Preservative-free formulation to be tested after NDA submission
Demodex blepharitis and MGD in China
(partnership with LianBio)
Rosacea
Lyme disease
Malaria
Candidate
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Demodex blepharitis
XDEMVY*
(TP-03)
Meibomian gland disease
(MGD)
Demodex blepharitis
(preservative free)
Preservative-free formulation to be tested after NDA submission
Demodex blepharitis
and MGD in China
(partnership with LianBio)
TP-04
Rosacea
Lyme disease
TP-05
Malaria
Target icon

Setting a target on unmet needs

Many parasite-mediated diseases have high clinical unmet needs. By applying our unique approach to research and development, we’re investigating solutions to target MGD, rosacea, Lyme disease prevention, and community reduction of malaria.

Investigating XDEMVY® (TP-03) for the potential treatment of meibomian gland disease (MGD)*

MGD is a broad term used to describe a dysfunction of the meibomian glands that may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease. We are evaluating XDEMVY in a Phase 2a trial for MGD.

TP-04 for the potential treatment of papulopustular rosacea (PPR)

PPR is a chronic skin disease characterized by facial redness, inflammatory lesions, and burning and stinging, which can flare up in response to certain triggers such as sun exposure or emotional stress. According to the US National Rosacea Society, approximately 16 million people in the United States are affected by rosacea. PPR is estimated to occur in 18% to 28% of patient with rosacea. We are developing TP-04 as a topical formulation.

TP-05 for potential Lyme disease prophylaxis and reduction of community malaria

Lyme disease is the most common vector-borne disease in the United States, caused by an infection of Borrelia bacteria following a bite by a tick. Estimates of annual cases of Lyme disease in the United States range from approximately 300,000 to 400,000. We are developing TP-05 as an oral formulation that is designed as a prophylactic drug against Lyme disease to eradicate the tick before it can transmit the Borrelia bacteria. TP-05 also has the potential to cause the death of mosquitos that transmit malaria. Malaria is one of the world’s highest unmet public health needs, with approximately 247 million cases and more than 600,000 deaths worldwide.

*XDEMVY is FDA approved only for the treatment of Demodex blepharitis. XDEMVY is currently being investigated in a Phase 2a trial for MGD.

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.